Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: Report from the SENTRY Antimicrobial Surveillance Program (1998-2009)

Diagnostic Microbiology and Infectious Disease

Volumn 68, Issue 3, 2010, Pages 334-336

  Jones, Ronald N ^a   Sader, Helio S ^b   Moet, Gary J ^b   Farrell, David J ^b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAROLINE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; BROTH DILUTION; DRUG SURVEILLANCE PROGRAM; GENE SEQUENCE; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PNEUMOCOCCAL INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; YOUNG ADULT;

EID: 77957892620     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.08.024     Document Type: Letter

References (12)

1. Chen D.K., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med. 1999, 341:233-239.
2. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition, M07-A8 2009, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 20th informational supplement (M100-S20) 2010, CLSI, Wayne, PA.
4. Gertz R.E., Li Z., Pimenta F.C., Jackson D., Juni B.A., Lynfield R., Jorgensen J.H., Carvalho Mda G., Beall B.W. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J. Infect. Dis. 2010, 201:770-775.
5. Henderson K.L., Muller-Pebody B., Blackburn R.M., Johnson A.P. Reduction in erythromycin resistance in invasive pneumococci from young children in England and Wales. J. Antimicrob. Chemother. 2010, 65:369-370.
6. Jacobs M.R., Good C.E., Windau A.R., Bajaksouzian S., Biek D., Critchley I.A., Sader H.S., Jones R.N. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 2010, 54:2716-2719.
7. Jones R.N., Fritsche T.R., Sader H.S. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 2005, 52:129-133.
8. Jones R.N., Jacobs M.R., Sader H.S. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int. J. Antimicrob. Agents 2010, 36:197-204.
9. Klugman K.P. Clinical impact of antibiotic resistance in respiratory tract infections. Int. J. Antimicrob. Agents 2007, 29(Suppl 1):S6-S10.
10. Mera R., Miller L.A., Fritsche T.R., Jones R.N. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb. Drug Resist. 2008, 14:101-107.
11. Moet, GJ, Biedenbach, DJ, Jones, RN, Stilwell, MG (2007) Secular trends in antimicrobial resistance among USA isolates of S. pneumoniae: a decade of experience from the SENTRY Antimicrobial Surveillance Program. In ASM, May 21-25, 2007. Abstr. A-033. Toronto, Ontario, Canada.
12. Patel S.N., Pillai D.R., Pong-Porter S., McGeer A., Green K., Low D.E. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J. Antimicrob. Chemother. 2009, 64:659-660.